Kanamycin was initially active against most gram-negative bacilli (3), but after extensive use of the drug emergence of increasing numbers of kanamycin-resistant organisms in the late 1960s led to the change to gentamicin as the aminoglycoside of choice in many hospitals (6) . Subsequently, decreased usage of kanamycin in recent years has resulted in increasing percentages of bacteria susceptible once again to clinically attainable concentrations of kanamycin (5) . Furthermore, reintroduction of kanamycin in our nurseries has not yet resulted in an increase in the percentages of kanamycinresistant organisms (5) . It is likely that kanamycin will continue to be a useful antimicrobial agent for treatment of gram-negative infections depending on the ecology of resistant strains, which will continue to vary with place, time, and general patterns of antimicrobial usage.
Most pediatric reference textbooks (7) recommend a kanamycin dosage of 15 mg/kg per day for patients beyond the neonatal period. This is generally given in divided dosages every 12 h in young infants and every 8 These data are presented in tabular form in Table 1 . In considering the patient group studied after a dosage of 5 mg/kg, an inverse relationship between age and serum half-life is evident; in the four patients 6 months of age or younger the mean serum half-life was 2.5 h, whereas in the 12 older patients it was 1.7 h. The overall mean serum half-life for the 5-mg/ kg group of patients was 1.9 h. A similar relationship was demonstrated between age and plasma clearance with patients 6 months of age and younger having a plasma clearance of 68 ml/min per 1.73 m2, whereas it was 129 ml/min per 1.73 m2 in the older children. The overall mean plasma clearance was 114 ml/min per 1.73 M2. The mean volume of distribution in the 5-mg/kg group was 441 ml/kg, with a range from 252 to 841 ml/kg. Similar data are presented in Table 1 for the 10 patients studied after a dosage of 10 mg/kg. The mean values for serum half-life, plasma clearance, and volume of distribution were 1.6 h, 128 ml/min per 1.73 mi2, and 439 ml/kg, respectively. A review of the literature for the proper dosage of kanamycin beyond the neonatal period reveals that sparse data exist to support the most commonly recommended (7) dosage of 15 mg of kanamycin/kg per day. Table 4 summarizes the available data (1, 4) for patients beyond the neonatal period. After a dose of 5 mg/ kg, more than one-half of the patients had peak serum concentrations below 15 ,ug/ml. The data obtained in the present study are consistent with those of Berger and Wehrle (1) and High et al. (4) and demonstrate that the currently recommended dosage of kanamycin of 5 mg/kg per dose intramuscularly for infants and children failed to produce serum concentrations in the optimal therapeutic range of 15 to 25 ,ug/ml. Preliminary data suggest that the dosage should be increased to 10 mg/kg per dose intramuscularly every 8 h.
Calculations based on the observed serum half-lives, peak and trough levels, and the fact that steady-state equilibrium is attained after 3.4 half-lives (10) predict that prolonged therapy with kanamycin in a dosage of 10 mg/kg per dose intramuscularly every 8 h will produce an average peak serum concentration of 18.4 ,ug/ml at steady state. The most extreme 1-h serum concentration based on the highest concentration observed in any patient to date is predicted to be 31.5 ,g/ml. Generally, the duration of kanamycin treatment in pediatrics is from 5 to 10 days (except in therapy of coliform meningitis). Therefore, with a 30-mg/kg per day schedule the total dosage will be between 
